EquityFlow
›
Companies
› DeuterOncology
DeuterOncology
Biotech
· Liège, BE
Clinical-stage developer of MET kinase inhibitors for lung cancer.
Funding history
Date
Round
Amount
Jan 2023
Series A
Belgian biotech DeuterOncology raised a €5.65M Series A from Newton Biocapital, Noshaq and Investsud Tech.
$5.7M
Investors
Investsud Tech
NOSHAQ
Newton Biocapital
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →